✦ LIBER ✦

The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1

✍ Scribed by C. Brandão; A. Barone; F. Carrilho; A. Silva; M. Patelli; C. Caramori; R. Focaccia; L. Pereira; M. Pedroso; F. Tatsch; M. Pessoa; the Pegasys Brazilian Study Group

Book ID: 108885915
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 160 KB
Volume: 13
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2006.00758.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized trial of 24 versus 48 weeks

A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan

✍ Yoshiaki Iwasaki; Yasushi Shiratori; Shuhei Hige; Shuhei Nishiguchi; Hitoshi Tak 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 343 KB

Treatment effects and predictors of a 24

Treatment effects and predictors of a 24-week course of interferon α-2b plus ribavirin combination therapy for patients with chronic hepatitis C

✍ Masahiko Tomimatsu; Yoshio Aizawa; Yoshimichi Chuganji; Hideo Ishizuka; Yoshiyuk 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

Placebo-controlled trial of 400 mg amant

Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection

✍ Michael von Wagner; Wolf Peter Hofmann; Gerlinde Teuber; Thomas Berg; Tobias Goe 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

The impact of amantadine on virologic response rates of interferon-based treatment of chronic hepatitis C is controversial. The aim of this study was to compare virological response rates in patients with chronic hepatitis C virus (HCV)-1 infection treated with 400 mg amantadine or placebo in combin

Triple combination of thymalfasin, pegin

Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study

✍ JORGE LUIS POO; F SÁNCHEZ-AVILA; D KERSHENOBICH; X GARCÍA-SAMPER; J GONGORA; M U 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

Prediction of nonSVR to therapy with peg

Prediction of nonSVR to therapy with pegylated interferon-α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment

✍ E. Lukasiewicz; M. Gorfine; L. S. Freedman; J.-M. Pawlotsky; S. W. Schalm; C. Fe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

Predicting treatment outcome following 2

Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6

✍ Esther Lukasiewicz; Kristoffer Hellstrand; Johan Westin; Carlo Ferrari; Avidan U 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

We sought to validate FIB-4 using data retrospectively collected from treatment-naive HIV/HCV patients. The original model was adapted in order to use AST and ALT levels expressed as times the upper limit of normality (ϫULN), as follows: (age [yr] ϫ AST [ϫULN]) ϫ 10/((PLT [10 9 /l]) ϫ (ALT [ϫULN]) 1